Brief: GRI Bio Partners with Respiratory Translational Research Collaboration to Advance NKT Regulation Technology
17/10/2023 14:51
Oct 17 (Reuters) - GRI Bio Inc GRI.O :
* GRI BIO ANNOUNCES PARTNERSHIP WITH THE RESPIRATORY
TRANSLATIONAL
RESEARCH COLLABORATION TO ADVANCE LEADING NKT REGULATION
TECHNOLOGY TARGETING EARLIER IN THE INFLAMMATORY CASCADE TO
MODULATE DISEASE PROGRESSION
* GRI BIO INC - GRI BIO RAPIDLY ADVANCING LEAD PROGRAM,
GRI-0621 A
TYPE 1 INVARIANT NKT ("INKT") ANTAGONIST IN DEVELOPMENT FOR
TREATMENT OF IPF
* GRI BIO INC - ON TRACK TO LAUNCH ITS PHASE 2A BIOMARKER
STUDY OF
GRI-0621 BEFORE YEAR-END
Source text for Eikon: ID:nGNX6Cf7CF
Further company coverage: GRI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GRI Bio
See all newsGRI Bio Inc reports results for the quarter ended June 30 - Earnings Summary
GRI Bio Inc expected to post a loss of $1.19 a share - Earnings Preview
Brief: Gri Bio Secures FDA Orphan Drug Designation For Gri-0621 (Tazarotene) In Idiopathic Pulmonary Fibrosis
GRI Bio Q1 net loss narrows on lower R&D expenses
GRI Bio raises $14.5 mln to fund operations into Q1 2027